Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial
Peter R. Galle(University Medical Center of the Johannes Gutenberg University Mainz), Richard S. Finn(University of California, Los Angeles), Shukui Qin(Nanjing General Hospital of Nanjing Military Command), Masafumi Ikeda(National Cancer Center Hospital East), Andrew X. Zhu(Massachusetts General Hospital), Tae‐You Kim(Seoul National University), Masatoshi Kudo(Kindai University), В. В. Бредер, Philippe Merle(Hôpital de la Croix-Rousse), Ahmed O. Kaseb(The University of Texas MD Anderson Cancer Center), Daneng Li(Beckman Research Institute), Sohail Mulla, Wendy Verret, Derek-Zhen Xu(Roche (China)), Sairy Hernandez, Beiying Ding, Juan Liu(Roche (China)), Chen Huang(Roche (China)), Ho Yeong Lim(Samsung Medical Center), Ann‐Lii Cheng, Michel Ducreux(Institut Gustave Roussy)
Cited by 372
Abstract
Related Papers
No related papers found
Powered by citation graph analysis